Metraipolis › archive › dc_becc5de3937c

Post marketing safety assessment of the novel postpartum depression drug, Zuranolone: evidence from real-world pharmacovigilance analysis based on the FDA… — Europe PMC PMID:40896228

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40896228
DOI
10.3389/fpsyt.2025.1517773
License (as archived)
solo-consultazione
Archived
2026-11-10T14:43:34.313Z
SHA-256 of the archived text
a64648ae038af5d4c9a23d5f14a9330853bfb8b6945996f093ded2f8c5f225d3
Stable URL of this page
https://metraipolis.com/documento/dc_becc5de3937c

How to cite

Post marketing safety assessment of the novel postpartum depression drug, Zuranolone: evidence from real-world pharmacovigilance analysis based on the FDA… — Europe PMC PMID:40896228 — Europe PMC (en), https://europepmc.org/article/MED/40896228 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_becc5de3937c (Metraipolis archive dc_becc5de3937c, sha256 a64648ae038af5d4c9a23d5f14a9330853bfb8b6945996f093ded2f8c5f225d3)
BibTeX
@misc{dcbecc5de3937c,
  title = {Post marketing safety assessment of the novel postpartum depression drug, Zuranolone: evidence from real-world pharmacovigilance analysis based on the FDA… — Europe PMC PMID:40896228},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40896228},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_becc5de3937c; sha256 a64648ae038af5d4c9a23d5f14a9330853bfb8b6945996f093ded2f8c5f225d3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40896228. Agents can read the archived copy with the MCP tool read_document.